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Abstract
Background: Paliperidone palmitate is a long-acting injectable atypical antipsychotic for the acute and
maintenance treatment of adults with schizophrenia. The recommended initiation dosing regimen is 234 mg on
Day 1 and 156 mg on Day 8 via intramuscular (deltoid) injection; followed by 39 to 234 mg once-monthly
thereafter (deltoid or gluteal). These post-hoc analyses addressed two commonly encountered clinical issues
regarding the initiation dosing: the time to onset of efficacy and the associated tolerability.
Methods: In a 13-week double-blind trial, 652 subjects with schizophrenia were randomized to paliperidone
palmitate 39, 156, or 234 mg (corresponding to 25, 100, or 150 mg equivalents of paliperidone, respectively) or
placebo (NCT#00590577). Subjects randomized to paliperidone palmitate received 234 mg on Day 1, followed by
their randomized fixed dose on Day 8, and monthly thereafter, with no oral antipsychotic supplementation. The
onset of efficacy was defined as the first timepoint where the paliperidone palmitate group showed significant
improvement in the Positive and Negative Syndrome Scale (PANSS) score compared to placebo (Analysis of
Covariance [ANCOVA] models and Last Observation Carried Forward [LOCF] methodology without adjusting for
multiplicity) using data from the Days 4, 8, 22, and 36 assessments. Adverse event (AE) rates and relative risks (RR)
with 95% confidence intervals (CI) versus placebo were determined.
Results: Paliperidone palmitate 234 mg on Day 1 was associated with greater improvement than placebo on Least
Squares (LS) mean PANSS total score at Day 8 (p = 0.037). After the Day 8 injection of 156 mg, there was
continued PANSS improvement at Day 22 (p ≤ 0.007 vs. placebo) and Day 36 (p < 0.001). Taken together with
results in the 39 mg and 234 mg Day 8 arms, these findings suggest a trend towards a dose-dependent response.
During Days 1 to 7, AEs reported in ≥2% of paliperidone palmitate subjects (234 mg) and a greater proportion of
paliperidone palmitate than placebo subjects were: agitation (3.2% vs. 1.3%; RR 2.52 [95% CI 0.583, 10.904]),
headache (4.0% vs. 3.8%; RR 1.06 [95% CI 0.433, 2.619]), and injection site pain (6.7% vs. 3.8%; RR 1.79 [95% CI 0.764,
4.208]). Days 8 to 36 AEs meeting the same criteria in the 156 mg Day 8 arm were: anxiety (3.1% vs. 2.5%; RR 1.24
[95% CI 0.340, 4.542]), psychotic disorder (2.5% vs. 1.3%; RR 1.99 [95% CI 0.369, 10.699]), dizziness (2.5% vs. 1.3%; RR
1.99 [95% CI 0.369, 10.699]), and injection site pain (2.5% vs. 1.3%; RR 1.99 [95% CI 0.369, 10.699]). Corresponding
Days 8 to 36 AEs in the 39 mg Day 8 group were: agitation (4.5% vs. 4.4%; RR 1.03 [95% CI 0.371, 2.874]), anxiety
(3.9% vs. 2.5%; RR 1.55 [95% CI 0.446, 5.381]), and psychotic disorder (2.6% vs. 1.3%; RR 2.07 [95% CI 0.384, 11.110])
while in the 234 mg Day 8 group it was anxiety (3.1% vs. 2.5%, RR 1.25 [95% CI 0.342, 4.570]).
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Background
For individuals with schizophrenia–whether a first epi-
sode or a relapse–the rapid and robust control of symp-
toms at well tolerated medication dosages are primary
goals to reduce emotional distress, minimize disruption
to the patient’s life, and reduce the risk of dangerous
behaviors [1]. Evidence also suggests that the prompt
improvement in symptoms may improve long-term out-
comes [2]. To realize these benefits, the effectiveness of
a therapeutic agent measured as an improvement in
symptoms, acceptable tolerability, and an early onset of
effect are important considerations in the choice of an
antipsychotic agent.
Rapid symptom control is a strong predictor of treat-
ment success and may be a valuable indicator of long-
term symptom control as well as a low rate of relapse
and rehospitalization, which may contribute to reducing
healthcare costs [3,4]. While some data suggest that
most symptom amelioration occurs within the first 2
weeks after introduction of antipsychotic treatment,
some patients require a longer time to respond. In a
recently published investigation of patterns of response
(defined as ≥3 0 %r e d u c t i o ni nP o s i t i v ea n dN e g a t i v e
Symptom Score [PANSS] from baseline) with an atypical
antipsychotic, approximately 36% of patients responded
within 2 weeks, while an additional 20% responded by
week 6 [5]. The American Psychiatric Association guide-
lines recommend a 2- to 4-week therapeutic trial prior
to changing a treatment regimen [1].
Paliperidone palmitate is a long-acting injectable for-
mulation of paliperidone, which is also formulated for
daily oral administration as paliperidone extended-release
(ER). Paliperidone palmitate is the palmitate ester of pali-
peridone. The dosing of paliperidone palmitate may be
expressed in terms of milligrams (mg) of paliperidone
palmitate or in terms of milligram equivalents (mg eq) of
the pharmacologically active fraction, paliperidone. Pali-
peridone palmitate expressed as 39, 156, and 234 mg is
equivalent to 25, 100, and 150 mg eq, respectively, of the
active fraction paliperidone. The pharmacokinetic prop-
erties of paliperidone palmitate allow for once-monthly
injections following two initiation doses given 1 week
apart [6-8]. Pharmacokinetic data indicate higher median
peak concentrations following paliperidone palmitate
administration into the deltoid rather than the gluteal
muscle, with similar area-under-the-curve (AUC) values
[7]. Given this, it is recommended that administration of
initiation doses of paliperidone palmitate be in the del-
toid muscle with maintenance dose administration being
interchangeable between deltoid and gluteal administra-
tion [7].
Paliperidone palmitate has been studied in several ran-
domized, double-blind controlled trials using various
dosing regimens [9-14]. A recently completed phase 3
trial was the first placebo-controlled study to assess pali-
peridone palmitate administered at the recommended
Day 1 dose of 234 mg by deltoid injection. Subjects then
received 39, 156, or 234 mg on Day 8 and monthly
thereafter (deltoid or gluteal). In this study, paliperidone
palmitate, without oral antipsychotic supplementation,
was associated with significant improvements in sympto-
matology with no unexpected tolerability findings in
adults with symptomatic schizophrenia, at all doses
tested [14].
An early, well-tolerated response to antipsychotic
treatment has important down-stream implications for
long-term symptom control, treatment adherence,
healthcare costs, and, consequently, clinical decision-
making. These post-hoc analyses of data from the pub-
lished trial [14] was designed to address two commonly
encountered clinical questions associated with the initia-
tion regimen of paliperidone palmitate: 1) when is the
onset of efficacy and; 2) how well is this initiation dose
tolerated. This report focuses on the subjects who
received 234 mg on Day 1 (deltoid) followed by 156 mg
on Day 8 (deltoid or gluteal). Data are also presented
for those who received 234 mg on Day 1 followed by 39
or 234 mg on Day 8.
Methods
Design
A 13-week double-blind, randomized, placebo-controlled
phase 3 trial (NCT#00590577) was conducted from
March 2007 to March 2008 at 72 centers in 8 countries
in North America, Europe, and Asia. Subjects with schi-
zophrenia and a PANSS total score of 70 to 120 (inclu-
sive) at screening and 60 to 120 (inclusive) at double-
b l i n db a s e l i n ew e r ee l i g i b l ef o rs t u d ye n r o l l m e n t .K e y
exclusion criteria included primary DSM-IV Axis I diag-
nosis other than schizophrenia, DSM-IV diagnosis of
active substance dependence within 3 months before
screening, history of treatment resistance (failure to
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medications with a minimum of 4 weeks duration at the
patient’s maximum tolerated dose), history of neurolep-
tic malignant syndrome, a relevant history of any signifi-
cant or unstable systemic disease, morbid obesity (body
mass index ≥40 kg/m
2), and circumstances that could
increase the risk of the occurrence of Torsade de
Pointes or sudden death. Further details of the study
design are reported by Pandina et al. [14].
Study Medications
The study consisted of a screening period of up to 7
days to washout disallowed psychotropic medications
followed by a 13-week double-blind treatment period.
On Day 1, eligible patients were randomly assigned
(1:1:1:1) to fixed doses of paliperidone palmitate 39, 156,
or 234 mg (equivalent to 25, 100, or 150 mg eq of the
active fraction paliperidone), or placebo, based on a
computer-generated randomization schedule balanced
by using permuted blocks of treatments and stratified by
center. On Day 1, all patients received a deltoid injec-
tion of paliperidone palmitate 234 mg or matching pla-
cebo. On Day 8, and then on Days 36 and 64, patients
received their assigned treatment per the randomization
schedule, injected in the deltoid or the gluteal muscle at
the discretion of the investigator. Patients were hospita-
l i z e df r o mD a y1( f i r s ti n j e c t i o n )u n t i la tl e a s ta f t e rt h e
second injection of study drug on Day 8. Antipsychotics
except study drug were prohibited during the double-
blind treatment period. Prior antiparkinsonian medica-
tions were to be washed out prior to baseline, but were
allowed during the study at the discretion of the investi-
gator if extrapyramidal symptoms [EPS] emerged or
worsened. Oral benzodiazepines were allowed for agita-
tion, anxiety, or sleep difficulties at the permitted maxi-
mum daily doses.
Assessments
Efficacy was assessed using PANSS total scores at Days
4, 8, 22, 36, 64, and 92 (or study endpoint). Tolerability
assessments included treatment-emergent adverse events
reports and adverse-event related study discontinuations.
Analysis Sets and Statistical Evaluations
Onset of efficacy and tolerability analyses were per-
formed on the intent-to-treat (ITT) analysis set, which
included all randomized patients who received at least
one dose of double-blind study medication and had
both the baseline and at least one post baseline efficacy
assessment. Changes from baseline in PANSS total
scores were estimated by Least Squares (LS) means and
compared between groups using an Analysis of Covar-
i a n c e( A N C O V A )m o d e la n dL a s tO b s e r v a t i o nC a r r i e d
Forward (LOCF) methodology, without adjustment for
multiplicity. Results on Days 4 and 8 were pooled for
the paliperidone palmitate dose arms (all received 234
mg of paliperidone palmitate on Day 1). At Days 22 and
36, data were analyzed for each paliperidone palmitate
dose group (corresponding to 39, 156, or 234 mg that
was administered at Day 8). The effect size (Cohen’sd )
for paliperidone palmitate relative to placebo in PANSS
change from baseline was calculated using Cohen’sd
with LS means and mean (standard error [SE]) from
ANCOVA model for treatment comparison. Onset of
efficacy was defined as the first timepoint at which the
change from baseline in the PANSS total score in the
paliperidone palmitate group was significant compared
to placebo (at the 2-sided nominal 5% level of signifi-
cance). Responder rates were defined as the proportion
of subjects with a ≥30% reduction from baseline in
PANSS total score. Pairwise comparisons were per-
formed using Cochran-Mantel-Haenszel tests controlling
for country.
Adverse events that occurred in ≥2% of paliperidone
palmitate subjects were summarized (by dose arm) and
compared to placebo, with determination of the relative
risk (RR) and 95% confidence interval (95% CI) asso-
ciated with paliperidone palmitate. RRs were considered
statistically significant when 95% CIs did not include 1.
No adjustments were made for multiplicity. Tolerability
associated with the initiation dosing regimen was also
assessed through analyses of treatment discontinuation
and adverse event reports (including extrapyramidal-,
metabolic- and potentially prolactin-related events) dur-
ing post-injection time periods of Days 1 to 7 and 8 to
36. Extrapyramidal events included akathisia, tremor,
dyskinesia, extrapyramidal disorder, movement disorder,
or parkinsonism. Metabolic events included metabolism
or nutritional disorders such as increased/decreased
appetite, increased/decreased weight, dyslipidemia(s), or
malnutrition. Potentially prolactin-related events
included reproductive system events, breast disorders,
and ejaculation disorders.
Results
Patient Disposition and Characteristics
Of 855 subjects screened, 652 (76%) were randomized to
either paliperidone palmitate (n = 488) or placebo (n =
164); 476 and 160, respectively, were in the ITT analysis
set (Figure 1). All ITT subjects randomized to paliperi-
done palmitate received a Day 1 dose of 234 mg; 161
were randomized to the 156 mg Day 8 treatment arm.
One-hundred sixty (160) and 155 subjects were rando-
mized to the 234 and 39 mg Day 8 treatment arms,
respectively. Administration of the Day 1 doses were
primarily (99%) in the deltoid muscle (3 paliperidone
palmitate and 1 placebo subject received the injection in
the gluteus). The Day 8 dose was administered in the
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mitate treatment arms and in 58% of those in the pla-
cebo treatment arm.
Baseline demographics and disease characteristics in
the ITT analysis set were similar across treatment arms
with a mean age of 39 years, 67% male, and 54% Cauca-
sian [14]. Mean (Standard Deviation [SD]) PANSS total
score scores were 86.8 (10.31) in the placebo group and
86.9 (11.99), 86.2 (10.77), and 88.4 (11.70) in the pali-
peridone palmitate 39, 156, and 234 mg Day 8 arms,
respectively. Atypical antipsychotics were commonly
used (70% of subjects) prior to enrollment, with oral ris-
peridone use reported by 34% to 41% of subjects across
the arms. Prior to baseline, approximately 30% of sub-
jects in each treatment arm were using an anti-EPS
medication (24% placebo and 35%, 30% and 33% in the
paliperidone palmitate 39, 156, and 234 mg Day 8 arms,
respectively) and approximately 60% were using a ben-
zodiazepine (65%, 67%, 58%, and 59%, respectively).
Effects on PANSS Total Scores
At Day 8 Timepoint
Paliperidone palmitate 234 mg administered on Day 1
was associated with a significantly greater improvement
than placebo on mean PANSS total score at the Day 8
assessment (LS mean [SE] change from baseline -8.21
[0.87] vs. -5.79 [1.20], p = 0.037) (Figure 2). The placebo
vs. treatment effect size (95% CI) was 0.19 (0.01, 0.37)
(Table 1).
At Day 22 and Day 36 Timepoints
After the Day 8 injection of 39, 156, or 234 mg, all pali-
peridone palmitate groups continued to show greater
PANSS total score improvement than placebo at the
subsequent Days 22 and 36 timepoints (Figure 2).
Among those administered the recommended 156 mg
Day 8 dose of paliperidone palmitate vs. placebo, the
Day 22 LS mean (SE) change from baseline was -9.9
(1.38) vs. -5.4 (1.4), p ≤ 0.007, with further improvement
at Day 36 (LS mean [SE] change from baseline: -13.2
[1.48] vs. -6.5 [1.50], p < 0.001). Corresponding effect
sizes for all dose arms are shown in Table 1. These
results suggest a dose-related effect.
The responder rates (≥30% reduction from baseline in
PANSS total score) were significantly higher with paliper-
idone palmitate (all dose groups) than with placebo by
the Day 36 timepoint (Figure 3). In the group receiving
the 156 mg Day 8 dose, the responder rate was 36.6%
compared to 20.6% with placebo (p = 0.002) (Figure 3).
Discontinuations and Benzodiazepine Use
Days 1 to 7
During Days 1 to 7, the percentage of patients who dis-
continued study participation was 2.9% in those who
received paliperidone palmitate (234 mg Day 1) and
4.4% in the placebo group (Table 2). During the week
following the first injection, the most common reason
for discontinuation in both groups was withdrawal of
consent (1.9% in placebo and 1.1% in paliperidone
palmitate).
Withdrawal due to adverse events was low in both
groups (0.8% [n = 4] in paliperidone palmitate and 1.3%
[n = 2] in placebo). Events that resulted in discontinua-
tion in the paliperidone palmitate group were: gastroe-
sophageal reflux, pain in extremity, suicidal ideation,
and toothache (1 subject); injection site pain (1 subject);
insomnia, schizophrenia, and tremor (1 subject); and
psychotic disorder (1 subject). Adverse events leading to
discontinuation in the two placebo-treated subjects were
schizophrenia (1 subject) and schizophrenia, increased
aspartate aminotransferase and increased blood lactate
dehydrogenase (1 subject).
Approximately half the patients in both groups
reported benzodiazepine use (Table 2).
Days 8 to 36
In the month following the Day 8 injection (Days 8 to
36), discontinuation rates were 32.5% in the placebo
group and 23.6% in the paliperidone palmitate 156 mg
Day 8 group (Table 2). Discontinuation due to adverse
Figure 1 Subject Randomization. Of 652 subjects enrolled in the double-blind treatment period, 488 were randomized (1:1:1:1) to paliperidone
palmitate (fixed dose of 39, 156, or 234 mg) and 164 to placebo. All those randomized to the fixed doses of paliperidone palmitate received 234
mg as the first initiation dose on Day 1, followed by administration of their fixed dose on Days 8, 36, and 64.
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group as well as the paliperidone palmitate 156 mg Day
8 treatment arm. Adverse events leading to discontinua-
tion in the 5 placebo-treated subjects were: increased
alanine aminotransferase and increased aspartate amino-
transferase (1 subject); nausea and vomiting (1 subject);
delusional disorder-persecutory type, musculoskeletal
stiffness, and tremor (1 subject); anxiety and schizophre-
nia (1 subject); and insomnia and schizophrenia (1 sub-
ject). Events leading to discontinuation in the
paliperidone palmitate 156 mg Day 8 group were: schi-
zophrenia (2 subjects); schizophrenia-paranoid type (1
subject); insomnia, otitis media-chronic, psychotic disor-
der, and toothache (1 subject); and injection site swel-
ling (1 subject).
No subject discontinued due to adverse events in the
paliperidone palmitate 39 mg Day 8 arm; 5 discontinued
in the 234 mg Day 8 treatment arm. Adverse events in
the latter group were psychiatric disorder and toothache
(1 subject); anxiety (1 subject); agitation, aspartate ami-
notransferase increase, toothache, and white blood cell
count decrease (1 subject); agitation, insomnia, and schi-
zophrenia (1 subject); and blood amylase increased and
cerebrovascular accident (1 subject).
Benzodiazepine use during this period was reported by
43.8% of the placebo arm and 33.5% of the paliperidone
palmitate 156 mg Day 8 arm. Rates were 42.6% in the
39 mg Day 8 arm and 40.0% in the 234 mg Day 8 arm
(Table 2).
Adverse Events
Days 1 to 7
The overall rate of adverse events during the week fol-
lowing the paliperidone palmitate 234 mg Day 1
Figure 2 Changes in PANSS Total Scores Over Time (LOCF) in the ITT Analysis Set (p-values for Paliperidone Palmitate vs. Placebo).
The administration of paliperidone palmitate 234 mg on Day 1 was associated with a significantly greater improvement than placebo on mean
PANSS total score at the Day 8 assessment (LS mean [SE] change from baseline -8.21 [0.87] vs. -5.79 [1.20], p = 0.037). In a dose-dependent
fashion, all paliperidone palmitate groups continued to show greater PANSS total score improvement than placebo at subsequent timepoints.
Table 1 Effect size for PANSS total change score: Paliperidone palmitate vs. placebo (95% CI)
Paliperidone Palmitate Treatment Group
234 mg (n = 459-Day 4; n = 476-Day 8) 39 mg (n = 155) 156 mg (n = 161) 234 mg (n = 160)
Day 4* 0.10 (-0.08, 0.29)
Day 8* 0.19 (0.01, 0.37)
Day 22 0.27 (0.05, 0.50) 0.30 (0.08, 0.52) 0.41 (0.19, 0.63)
Day 36 0.28 (0.06, 0.50) 0.43 (0.21, 0.64) 0.40 (0.18, 0.62)
*All paliperidone palmitate dose groups received 234 mg on Day 1, and their assigned dose on Day 8.
Type of effect size is Cohen’s d; p-value is from two-sided Z test.
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(38.0% [181/476] vs. 43.1% [69/160], respectively). With
the exception of one report of schizophrenia in a pla-
cebo-treated subject, no other adverse events were rated
as serious.
Adverse events reported in ≥2% of paliperidone palmi-
tate treated subjects and in a greater proportion of pali-
peridone palmitate than placebo-treated subjects were
agitation (3.2% vs. 1.2%; RR 2.52 [95% CI 0.583,
10.904]), headache (4.0% vs. 3.8%; RR 1.06 [95% CI
0.433, 2.619]), and injection site pain (6.7% and 3.8%;
RR 1.79 [95% CI 0.764, 4.208]) (Figure 4A). The RRs
were not statistically significant as determined by 95%
CIs.
The incidence of any EPS-related event reports during
Days 1 to 7 was 3.6% (17/476) in the paliperidone
palmitate 234 mg group and 3.1% (5/160) in the placebo
group. The use of anti-EPS medications was 5.5% (26/476)
and 7.5% (12/160), respectively.
Metabolic and potentially prolactin-related events
were reported in < 2% of those administered paliperi-
done palmitate 234 mg or placebo on Day 1.
Days 8 to 36
The adverse event rate during the month following the
Day 8 injection was 38.5% (62/161) in the paliperidone
palmitate 156 mg Day 8 group and 41.3% (66/160) in
the placebo group. Rates in the other paliperidone pal-
mitate dose groups were 36.8% (57/155) with 39 mg
Day 8, and 41.3% (66/160) with 234 mg Day 8.
A total of 39 subjects reported adverse events that
were rated as serious during Days 8 to 36: 29 paliperi-
done palmitate subjects (6.1%) and 10 placebo subjects
Figure 3 Responders: ≥30% Improvement from Baseline in PANSS Total Scores. The responder rates were significantly higher with
paliperidone palmitate (all dose groups) than with placebo by the Day 36 timepoint.
Table 2 Study Discontinuations and Benzodiazepine Use, by Treatment Group and Time Period
Days 1 to 7 Days 8 to 36
Placebo (n
= 160)
Paliperidone
palmitate 234 mg
(n = 476)
Placebo (n
= 160)
Paliperidone
palmitate 39 mg
(n = 155)
Paliperidone
palmitate 156 mg
(n = 161)
Paliperidone
palmitate 234 mg
(n = 160)
Discontinuations, No.,
(%)
7 (4.4%) 14 (2.9%) 52 (32.5%) 38 (24.5%) 38 (23.6%) 32 (20.0%)
Discontinuation
Reason, No., (%)
Lack of efficacy 2 (1.3%) 3 (0.6%) 29 (18.1%) 14 (9.0%) 14 (8.7%) 16 (10.0%)
Withdrawal of consent 3 (1.9%) 5 (1.1%) 12 (7.5%) 12 (7.7%) 17 (10.6%) 10 (6.3%)
Adverse event 2 (1.3%) 4 (0.8%) 5 (3.1%) 8 (5.2%) 5 (3.1%) 5 (3.1%)
Lost to follow-up 0 0 6 (3.8%) 4 (2.6%) 1 (0.6%) 1 (0.6%)
Other 0 2(0.4%) 0 0 1 (0.6%) 0
Benzodiazepine Use,
No. (%)
80 (50%) 247 (51.9%) 70 (43.8%) 66 (42.6%) 54 (33.5%) 64 (40.0%)
*All paliperidone palmitate dose groups received 234 mg on Day 1, and their assigned dose on Day 8.
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cebo arm were: acute psychosis (1 subject); persecutory
type delusional disorder (1 subject); psychotic disorder
(2 subjects); schizophrenia (5 subjects); electrocardio-
gram change (1 subject); and non-cardiac chest pain (1
subject). Serious adverse events reported in those receiv-
ing the recommended Day 8 dose of 156 mg were: anxi-
ety (1 subject); psychotic disorder (4 subjects);
schizophrenia, paranoid type (1 subject); and schizo-
phrenia (4 subjects).
Serious adverse events reported in the 39 mg Day 8 arm
during this period were: agitation (1 subject); depression
(1 subject); auditory hallucination (1 subject); insomnia
(1 subject); psychotic disorder (2 subjects); schizophrenia
(5 subjects); suicidal ideation (3 subjects); diverticulitis
(1 subject); and syncope (1 subject). Those reported in the
234 mg Day 8 arm were: anxiety (1 subject); depression
(1 subject); psychotic disorder (1 subject); schizophrenia
(4 subjects); and cerebrovascular accident (1 subject).
Note that a given patient may have reported more than
one serious adverse event.
In the paliperidone palmitate group receiving the
recommended initiation dosing (234 mg Day 1/156 mg
Day 8), the adverse events reported in ≥2% of this group
and in a greater percentage of paliperidone palmitate
than placebo subjects were anxiety (3.1% vs. 2.5%; RR
1.24 [95% CI 0.340, 4.542]), psychotic disorder (2.5% vs.
1.3%; RR 1.99 [95% CI 0.369, 10.699]), dizziness (2.5%
vs. 1.3%; RR 1.99 [95% CI 0.369, 10.699]), and injection
site pain (2.5% vs. 1.3%; RR 1.99 [95% CI 0.369, 10.699])
(Figure 4B). These RRs were not statistically significant,
as determined by 95% CIs.
In the paliperidone palmitate 39 mg Day 8 arm (Fig-
ure 4C), the adverse events reported in ≥2% of this
group and in a greater percentage of paliperidone palmi-
tate than placebo subjects were agitation (4.5% vs. 4.4%;
RR 1.03 [95% CI 0.371, 2.874]), anxiety (3.9% vs. 2.5%;
RR 1.55 [95% CI 0.446, 5.381]), and psychotic disorder
(2.6% vs. 1.3%; RR 2.07 [95% CI 0.384, 11.110]). In the
234 mg Day 8 group (Figure 4D), the only adverse event
meeting the criteria was anxiety (3.1% vs. 2.5%, RR 1.25
[95% CI 0.342, 4.570]).
Figure 4 Adverse Events in ≥2% of Paliperidone Palmitate and in a Higher Percentage of Paliperidone Palmitate than Placebo
Subjects. Adverse events meeting these criteria during Days 1 to 7 are shown in Panel A for subjects received paliperidone palmitate 234 mg
Day 1 (rates and relative risks versus placebo with 95% CIs); none were statistically significant as determined by 95% CIs. Adverse events that met
these criteria during Days 8 to 36 are shown in Panel B for the paliperidone palmitate 156 mg Day 8 group, Panel C for the 39 mg Day 8 group,
and Panel D for the 234 mg Day 8 group. None were statistically significant as determined by 95% CIs.
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8 to 36 were 3.7% (6/161) in the paliperidone palmitate
156 mg Day 8 arm and 4.4% (7/160) in the placebo arm
(RR 0.8518; 95% CI 0.293, 2.48). Specific extrapyramidal
symptoms were reported in < 2% of subjects in any
treatment arm, with the exception of akathisia, reported
in 2.5% (4/160) of the paliperidone palmitate 234 mg
Day 8 arm and 3.1% (5/160) of the placebo arm (RR
0.800, 95% CI 0.219, 2.925).
The use of anti-EPS medications during Days 8 to 36
was 9.0% (14/155), 9.9% (16/161), and 6.3% (10/160) in
those receiving 39, 156, and 234 mg on Day 8, respec-
tively. The rate was 6.3% (10/160) in the placebo group.
Metabolic events and potentially prolactin-related
events were reported in < 2% of subjects in each paliper-
idone palmitate arm and the placebo arm.
Discussion
Two common clinical questions regarding the initiation
dosing of paliperidone palmitate, specifically the time to
onset of efficacy and the associated tolerability, were
addressed in these post-hoc analyses of a large, double-
blind, placebo-controlled trial. The question of when
clinicians and patients can anticipate an improvement in
symptoms is integral to clinical decision-making, particu-
larly when managing a symptomatic patient with schizo-
phrenia and planning a treatment strategy. While some
clinicians may prefer to initiate paliperidone palmitate at
a lower than the recommended initiation regimen due to
tolerability concerns, previously published data suggest
this may result in sub-therapeutic plasma levels and poor
longer-term clinical response in some patients [9,11].
Thus, data were presented in this report for the early
days and weeks following the initiation regimen to exam-
ine the efficacy and tolerability of the recommended
initiation doses for paliperidone palmitate.
Findings showed significantly greater symptom improve-
ment by Day 8 with paliperidone palmitate (234 mg on
Day 1) compared to placebo, without oral antipsychotic
supplementation, with this effect maintained after the
156 mg injections through Day 64, as well as at study end-
point [14]. When looking across the treatment arms, a
trend towards a dose-dependent response was observed
during the first 36 days of this study, again consistent with
the data reported through study endpoint [14]. Also of
note, the effect size vs. placebo for PANSS data illustrate
an increasing improvement over time with the 156 mg
dose (0.30, 0.43, 0.42, and 0.49 at Days 22, 36, 64, and end-
point, respectively), and the 234 mg dose (0.41, 0.40, 0.48,
and 0.55, respectively). The 39 mg arm had lower and rela-
tively constant effect sizes from Day 22 through endpoint
(0.27, 0.28, 0.26, and 0.28, respectively). The early reduc-
tion in mean PANSS score shown here is supported by
that from a non-inferiority trial [15], where PANSS
improvement was similar at the Day 4 timepoint for sub-
jects receiving an initial injection of paliperidone palmitate
at 234 mg compared to oral risperidone given at 1 to 6 mg
per day.
The clinical improvement observed with the initiation
doses of paliperidone palmitate in this study is sup-
ported by the attainment of therapeutic serum concen-
trations of paliperidone reported in clinical and
pharmacokinetic modeling analyses [7,8,14]. Following a
single intramuscular dose, the release of paliperidone
into the systemic circulation occurs as early as Day 1,
with a gradual rise to reach maximum plasma concen-
trations at a median of 13 days [6]. The two initial
doses of paliperidone palmitate (234 mg Day 1/156 mg
Day 8) into the deltoid help attain therapeutic concen-
trations rapidly, with the AUC profiles being dose pro-
portional over the 39 to 234 mg dose range [6]. In
studies that used lower doses of paliperidone palmitate
and initiation dose administration into the gluteal mus-
cle, an onset of efficacy by Day 8 was not consistently
observed [9,11].
With respect to tolerability concerns with the recom-
mended paliperidone palmitate initiation dosing, this
study did not reveal unexpected adverse events or high
rates of specific adverse events in the first week or
subsequent month after the initiation injections. In addi-
tion, overall treatment discontinuations and discontinua-
tions due to adverse events were generally low during
this time. However, these are data from a single clinical
study. Further, the relative risk analysis requires com-
ment. This analysis was undertaken with the intent of
providing a useful way identifying adverse events that
may be more likely to occur with active treatment as
compared with placebo. Findings were that events such
as agitation, anxiety, dizziness, headache, injection site
pain, and psychotic disorder had a relative risk ranging
from approximately 1.1 to 2.5 during the first month of
treatment. Although these relative risks were not statis-
tically significant, as determined by the 95% CIs, they
may be clinically relevant providing useful information
for clinicians to consider when initiating treatment with
paliperidone palmitate. Additionally, it must be noted
that the analysis of this relatively small database is not
sufficient to identify rare treatment-related events.
Extrapyramidal symptoms such as parkinsonism,
akathisia, dyskinesia, and dystonia are also an area of
concern with respect to the tolerability of an antipsycho-
tic regimen. Substantial literature supports that the inci-
dence of these events as well as the time of onset differ
substantially [16,17]. In terms of onset, dystonic reac-
tions and akathisia generally occur within the first few
hours to days of treatment while parkinsonism occurs
within the first few weeks and tardive dyskinesia or dys-
tonia generally appearing after months or years of
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pyramidal symptoms is generally considered to be lower
with atypical compared with typical antipsychotics–
however, the risk for these events varies among the
agents in each class. Within the atypical class of agents
the risk for extrapyramidal events is often dose-related
[16]. In this analysis, the incidence of extrapyramidal
symptoms was less than 2%, with akathisia being the
only extrapyramidal symptom having an incidence of
> 2% (2.5%) during Days 8 to 36 at the highest dose of
paliperidone palmitate (234 mg).
One must also consider that this study was not
designed to assess onset of efficacy or the tolerability
associated with the initiation regimen. Therefore, these
findings are somewhat limited by the timepoints that
were assessed (i.e., Days 4, 8, 22, 36) and data collected
at these visits. For example, more timepoints would be
valuable to assess onset. It should also be noted that
while commonly used criteria were applied to define
onset as well as response, other criteria could result in
different outcomes. Further, t h e s ec r i t e r i aw e r ea p p l i e d
to a population of subjects enrolled in a large double-
blind clinical trial and these findings may not generalize
to patient populations with different characteristics.
Also, the results presented here are population-based
data that do not fully address the heterogeneity that is
associated with individual treatment response. That is,
mean responses from a population address probabilities
of clinical response but do not predict the response for
a particular patient. Finally, it should be pointed out
that there was a substantial placebo response observed
in this trial. This is not uncommon in studies of patients
with schizophrenia and, nevertheless, the effect size data
for paliperidone palmitate compared to placebo suggests
a clinically meaningful dose- and time-dependent treat-
ment effect in this population.
Conclusions
In this study, the initiation regimen of paliperidone pal-
mitate of 234 mg on Day 1 and 156 mg on Day 8 was
associated with a significant improvement in symptoms
by Day 8 that continued at the subsequent Day 22 and
Day 36 timepoints among subjects with symptomatic
schizophrenia. There was a trend towards a dose-depen-
dent response observed across the dosage groups. There
were no unusual or unexpected tolerability findings
noted during either the first week or month following
paliperidone palmitate treatment initiation.
Endnote
a. The dosing used in this clinical study aligns with the
recommended initiation regimen of paliperidone palmi-
tate (i.e., 234 mg on Day 1, 156 mg on Day 8); however,
the dosage regimen recommends that these injections
are both given in the deltoid muscle, with gluteal muscle
injections being an option after the Day 8 dose [6].
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